A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non small cell lung cancer (NSCLC). Interim analysis of toxicity. (GLOT-GFPC NPC 95-01 study)

Fournel, P.; Robinet, G.; Penzel, Thomas; Souquet, P.J.; Léna, H.; Vergnenègre, A.; Michel-Montpeyroux, F; Mornex, F.; Jp, Daurès

doi:10.1016/s0169-5002(00)80301-3

Cited by 14 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The overall survival was not significantly different between the two groups (median survival of 13.8 months in the sequential arm and 15 months in the concomitant arm) [67]. These results are summarized in Table 3.…”

Section: Chemotherapy and Locally Advanced Diseasementioning

confidence: 75%

Expanding role of chemotherapy in lung cancer

2006

View full text Add to dashboard Cite

Section: Chemotherapy and Locally Advanced Diseasementioning

confidence: 75%

Expanding role of chemotherapy in lung cancer

2006

View full text Add to dashboard Cite

“…The optimal way to deliver chemotherapy is concurrent with radiotherapy as seen in several randomized controlled trials [9][10][11]15]. The combination of cisplatin and vinorelbine showed a favorable toxicity profile when given together with radiotherapy and after 2 cycles of induction chemotherapy with the same drugs [12].…”

Section: Discussionmentioning

confidence: 99%

“…Chemotherapy given concurrently with radiotherapy has shown to prolong local control in-field [6,7] as well as progression-free survival [8]. At present, simultaneous radiotherapy and full-dose chemotherapy is the most effective treatment which is, however, limited by increased acute toxicity [9][10][11]. The combination of cisplatin with 3 modern cytotoxic agents (gemcitabine, paclitaxel and vinorelbine) given as induction chemotherapy and followed by the same drugs concurrent with radiotherapy was tested in the study CALBG 9431.…”

Section: Introductionmentioning

confidence: 99%

Oral Vinorelbine and Cisplatin with Concomitant Radiotherapy in Stage III Non-Small Cell Lung Cancer (NSCLC): A Feasibility Study

Beckmann

Fietkau²,

Huber³

et al. 2006

Oncol Res Treat

View full text Add to dashboard Cite

Background: Concurrent chemoradiotherapy has improved survival in inoperable stage III non-small cell lung cancer (NSCLC). This phase I trial was performed in order to establish a dose recommendation for oral vinorelbine in combination with cisplatin and simultaneous radiotherapy. Patients and Methods: Previously untreated patients with stage IIIB NSCLC received concurrent chemoradiotherapy with 66 Gy and 2 cycles of cisplatin and oral vinorelbine which was administered at 3 different levels (40, 50 and 60 mg/m2). This was to be followed by 2 cycles of cisplatin/ vinorelbine oral consolidation chemotherapy. The study goal was to determine the maximal recommended dose of oral vinorelbine during concurrent treatment. Results: 11 stage IIIB patients were entered into the study. The median radiotherapy dose was 66 Gy. Grade 3-4 toxicity included neutropenia, esophagitis, gastritis and febrile neutropenia. The dose-limiting toxicity for concurrent chemoradiotherapy was esophagitis. 9 patients received consolidation chemotherapy, with neutropenia and anemia/thrombocytopenia grade 3 being the only toxicities. The overall response was 73%. Conclusion: Oral vinorelbine 50 mg/m2 (days 1, 8, 15 over 4 weeks) in combination with cisplatin 20 mg/m2 (days 1-4) is the recommended dose in combination with radiotherapy (66 Gy) and will be used for concurrent chemoradiotherapy in a forthcoming phase III trial testing the efficacy of consolidation chemotherapy in patients not progressing after chemoradiotherapy.

show abstract

“…However, the gains are modest, with median survivals being 13.2 months versus 11.4 months, and 5-year survivals of 8% and 5% after sequential chemo-radiotherapy and radiotherapy, respectively. Three completed phase III clinical trials have addressed the issue of sequential versus concurrent chemo-radiotherapy in stage III NSCLC, and two have reported a small improvement in median survival of 2.5 months [10,16], while the third trial did not show any survival benefit [17]. The Japanese trial was conducted in a highly selected patient population with a requirement that radiation fields be less than one half of a single lung [16].…”

Section: Concurrent Versus Sequential Chemo-radiotherapymentioning

confidence: 99%